| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1097-0215(20000515)86:4<538::AID-IJC16>3.0.CO;2-G |
| P698 | PubMed publication ID | 10797269 |
| P2093 | author name string | A Knuth | |
| D Jäger | |||
| E Jäger | |||
| T E Reichert | |||
| J Karbach | |||
| H Höhn | |||
| A Necker | |||
| C Neukirch | |||
| Z Zidianakis | |||
| J Orth | |||
| M Maeurer | |||
| A Bakhshandeh-Bath | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 538-547 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides | |
| P478 | volume | 86 |
| Q30310231 | Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy |
| Q34335855 | Autoimmune melanocyte destruction in vitiligo |
| Q34517586 | Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage |
| Q38877813 | Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning |
| Q34547192 | Clinical cancer vaccine trials |
| Q77677711 | Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses |
| Q39596165 | Comparison of bone morphogenetic protein-2 and osteoactivin for mesenchymal cell differentiation: effects of bolus and continuous administration |
| Q33421740 | Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha |
| Q35595698 | Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. |
| Q35080073 | Evidence for an autoimmune pathogenesis of vitiligo |
| Q51886628 | Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. |
| Q36908627 | Functional heterogeneity of vaccine-induced CD8(+) T cells |
| Q40766619 | Human leucocyte antigen-A2 restricted and Mycobacterium tuberculosis 19-kDa antigen-specific CD8+ T-cell responses are oligoclonal and exhibit a T-cell cytotoxic type 2 response cytokine-secretion pattern. |
| Q42164689 | Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition |
| Q34353878 | Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer |
| Q34167925 | Immunity against cancer: lessons learned from melanoma. |
| Q30440584 | Immunity to melanoma antigens: from self-tolerance to immunotherapy |
| Q34383950 | Immunotherapy of melanoma |
| Q39625498 | Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis. |
| Q34167930 | In vivo tracking of tumor-specific T cells |
| Q57209300 | Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen |
| Q33378044 | MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. |
| Q35129926 | Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? |
| Q78567097 | Melanoma vaccines |
| Q37820489 | New approaches to the development of adenoviral dendritic cell vaccines in melanoma. |
| Q52013647 | Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. |
| Q35041705 | Prospects for immunotherapy of malignant disease |
| Q93037335 | Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo |
| Q34956078 | The T-cell response in patients with cancer |
| Q35005960 | Towards patient-specific tumor antigen selection for vaccination |
| Q34632077 | Tracking T cells with tetramers: new tales from new tools |
| Q34293096 | Vaccines for colorectal cancer |
| Q37801388 | Vitiligo, reactive oxygen species and T-cells |
| Q84192866 | [Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy] |
Search more.